Hoth Therapeutics, Inc.

HOTH

US44148G2049

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:30:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.16 ^USD	-0.85%		-2.97%	-19.44%

Mar. 28	Hoth Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 19	Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	MT

Hoth Therapeutics, Inc. Doses First Patient in its Phase 2a Clinical Trial of HT-001 for Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors

July 25, 2023 at 08:12 am EDT

Hoth Therapeutics, Inc. announced that the first patient has been dosed in its Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). This clinical trial is a randomized, placebo-controlled, parallel Phase 2a dose- ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi.

Latest news about Hoth Therapeutics, Inc.

Hoth Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected	Mar. 19	MT
Hoth Therapeutics, Inc. Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ	Mar. 19	CI
HC Wainwright Starts Hoth Therapeutics With Buy Rating, $4 Price Target	Feb. 05	MT
Hoth Therapeutics Shares Rise 14% After FDA Clearance for HT-001 Trial Amendments	Jan. 18	DJ
Hoth Therapeutics Receives FDA Approval to Expand HT-001 Clinical Trial to Treat Severely III Patients	Jan. 18	CI
Hoth Therapeutics Gets University of Miami Approval to Enroll Patients in Skin Toxicities Treatment Trial; Shares Rise	Dec. 27	MT
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial for Cancer Patients of HT-001 At University of Miami	Dec. 27	CI
Hoth Therapeutics Announces Successfully Completed Manufacturing of its Cancer Fighting HT-KIT for Ind-Enabling Studies	Dec. 05	CI
Hoth Therapeutics to Advance HT-KIT After Positive Feedback From FDA	Nov. 14	MT
Hoth Therapeutics, Inc. Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT	Nov. 14	CI
Hoth Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients	23-10-02	CI
Hoth Therapeutics Completes $2.89 Million Registered Direct Stock Offering	23-09-15	MT
Hoth Therapeutics, Inc. announced that it has received $2.892449 million in funding	23-09-14	CI
EF Hutton Cuts Hoth Therapeutics Price Target to $7.50 From $12, Maintains Buy Rating	23-09-14	MT
Hoth Therapeutics Prices Registered Direct Offering at $2.63 per Share	23-09-13	MT
Hoth Therapeutics, Inc. Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia	23-09-13	CI
Hoth Therapeutics, Inc. announced that it expects to receive $2.892449 million in funding	23-09-12	CI
Hoth Therapeutics Seeks FDA Meeting to Discuss HT-KIT Cancer Drug Program	23-09-11	MT
EF Hutton Assumes Hoth Therapeutics at Buy With $14 Price Target	23-08-23	MT
Hoth Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Hoth Therapeutics, Inc. Doses First Patient in its Phase 2a Clinical Trial of HT-001 for Treatment of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors	23-07-25	CI
Hoth Therapeutics Says FDA Approved Protocol Change in Trial of Treatment for Cancer Therapy-Induced Skin Disorders	23-07-19	MT
Hoth Therapeutics, Inc. Receives Protocol Approval for HT-001 Cancer Therapeutic	23-07-19	CI

Chart Hoth Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); a treatment for traumatic brain injury and ischemic stroke (HT-TBI) and a treatment and/or prevention for Alzheimerâs or other neuroinflammatory diseases (HT-ALZ). It also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for acne as well as inflammatory bowel diseases (HT-003). Its development products include HT-001, HT-KIT, HT-ALZ, and HT-TBI. Its BioLexa Platform is a proprietary, patented, drug compound platform for the treatment of eczema. The Company also has interests in certain other assets being developed by third parties including a treatment for patients with lupus.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.16 USD

Average target price

5.5 USD

Spread / Average Target

+374.14%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HOTH THERAPEUTICS, INC.	-19.44%	5.67M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals